PrecisionMed
Inc., the world's leading supplier of human cerebrospinal fluid
(CSF), today announced enrollment of the first donor into the
PrecisionMed Amyotrophic Lateral Sclerosis (ALS) Registry. The
PrecisionMed ALS Registry is a biological sample bank of DNA and
longitudinal CSF, RNA, serum and plasma linked to clinical data
utilizing PrecisionMed's clinical data procurement and clinical sample
management capabilities. The PrecisionMed ALS Registry is expected to be
of value for the discovery and/or validation of biomarkers for
neurodegenerative disease.
The PrecisionMed ALS Registry will enroll up to 2000 donors, with either
sporadic or familial ALS. All donors will be recruited, evaluated,
clinically studied, and sampled from up to 10 experienced investigative
sites in the US. Key aspects of donors' clinical status will be
evaluated every four months with simultaneous biological sampling.